Triple-negative breast cancer (TNBC), defined by a lack of expression of both estrogen (ER) and progesterone receptor (PR) as well as human epidermal growth factor receptor 2 (Her2), is the most aggressive subgroup of breast cancer and accounts for 12–18% of all invasive breast cancers (2). This evidence concerns the gene ERBB2 and invasive breast carcinoma.